Other matters Principal activity Creditor payment policy The principal activities of the Group are the development, The Companys policy, which is also applied by the Group, is to manufacture and marketing of a broad range of generic and settle terms of payment with suppliers when agreeing the terms in-licensed pharmaceutical products in solid, semi-solid, liquid of each transaction, ensure that suppliers are made aware of the and injectable final dosage forms.
Hikmas operations are terms of payment and abide by the terms of payment.
Trade conducted through three business segments: Branded creditors of the Company at 31 December 2007 were equivalent Pharmaceuticals, Generic Pharmaceuticals and Injectable to 81 days purchases, as compared to 74 days at 31 December Pharmaceuticals.
The majority of Hikmas operations are in 2006, based on the average daily amount invoiced by suppliers the MENA region, the United States and Europe.
The Groups net sales, gross profit and operating profit are Charitable and political contributions shown by business segment in Note 3 to the consolidated During the year the Group made charitable donations of financial statements.
approximately $1.3 million, principally to local charities serving the communities in which the Group operates.
Donations of Results and dividends medicines accounted for approximately $590,000 of total The Groups profit for the year attributable to shareholders in donations made.
The Board is recommending a final dividend of 4.0 cents per share approximately 2.0 pence.
The Group does not make political donations.
The proposed final dividend will be paid on 2 June 2008 to shareholders on the register on 2 May 2008, subject to approval Capital structure at the Annual General Meeting.
The Company has one class of Ordinary Shares which carries no right to fixed income.
Each share carries the right to one vote at Directors and their Interests general meetings of the Company.
As at 31 December 2007, The names of the Directors as at the date of this report, together the Company had 898 ordinary shareholders and 170,733,807 with details of their roles, backgrounds and abilities, are set out in Ordinary Shares of 10 pence each in issue.
During 2007 the the Directors biographies on page 34.
Details of the independence Company issued 2,569,000 Ordinary Shares pursuant to the of Non-Executive Directors are set out in the Corporate exercise of options under the Hikma Pharmaceuticals PLC Governance report on pages 36 to 39.
The Executive and Non-Executive Directors served the Company There are no specific restrictions on the size of a holding nor throughout the year, save for Said Darwazah, who was the transfer of shares, which are both governed by the general appointed as a Director and Chief Executive Officer on 1 July provisions of the Companys Articles of Association and 2007.
Having been appointed by the Directors, Mr Darwazah will prevailing legislation.
The Directors are not aware of any offer himself for re-election at the next Annual General Meeting.
agreements between holders of the Companys shares that may have resulted in restrictions on the transfer of securities Details of directors share options are provided in the or on voting rights.
No person has any special rights with regard Remuneration Committee report on pages 44 to 53. to the control of the Companys share capital.
With regard to The Directors who held office on 31 December 2007 had the appointment and replacement of directors, the Company is the following interests in the shares and debentures of the governed by the Articles of Association, the Combined Code, Company at the year end and at 17 March 2008, being the and prevailing legislation.
Substantial shareholdings Ordinary Shares of 10 pence As at 31 December 2007, the Company had been notified 1 January 31 December 17 March Director 2007 2007 2008 pursuant to sections 89A to 89L of the Financial Services and Samih Darwazah 1,394,506 1,706,506 1,875,450 Markets Act 2000 and Rule 5.1.
2R of the Disclosure and Transparency Rules of the UKLA of the following interests in the Said Darwazah 612,780 673,445 voting rights attaching to shares in the capital of the Company: Mazen Darwazah 561,958 561,958 617,591 Name of Number of Percentage Shareholder shares held Michael Ashton 4,566 4,566 4,566 Darhold Limited 52,649,972 30.83% Ali Al Husry 1,109,748 1,109,748 1,109,748 Capital Research and Management Breffni Byrne 10,000 10,000 10,000 Company 10,223,003 6.08% Ronald Goode 6,000 6,000 Legal & General Group PLC 5,181,598 3.05% Sir David Rowe-Ham 10,000 10,000 10,000 No further notifications were received between 31 December Total shares 3,090, 778 4,021,558 4,306,800 2007 and the date of this document.
However, as a result of Whilst Said Darwazah owned shares on 1 January 2007, he was not appointed shares subscribed in the placing undertaken by the Company as a director of the Company until 1 July 2007. on 17 January 2008, Darhold Limited now holds 57,883,028 Ordinary Shares, though no notification obligation arose as a result of this subscription.
42 Hikma Pharmaceuticals PLC Annual report 2007 Other matters The Takeover Code Rule 9 Significant agreements and contracts At the Annual General Meeting held on 6 June 2007, a vote Due to the nature of the Groups business, members of the of the independent shareholders of the Company approved Group are party to agreements that could alter or be terminated the award of up to an aggregate of 437,141 Ordinary Shares upon a change or control of the Group following a takeover.
pursuant to the Companys 2006 Long-Term Incentive Plan to However, none of these agreements is individually deemed to be Said Darwazah and Mazen Darwazah the LTIP Holders.
significant in terms of its potential impact on the business of the Because of the relationship of the LTIP Holders with Darhold Group taken as a whole.
The Directors are not aware of any Limited, who at the time of the Annual General Meeting held agreements between the Company and its Directors or 52,649,972 Ordinary Shares representing 31.129% of the issued employees that provide for compensation for loss of office or share capital of the Company at 25 April 2007, being the latest employment that occurs because of a takeover bid.
practicable date prior to the publication of the Notice of Annual General Meeting, each of the LTIP Holders together with certain Auditors other identified individuals at that date was treated as acting in Each of the persons who is a Director of the Company at the concert with Darhold Limited for the purposes of the Takeover date when this report was approved confirms that: Code the Concert Party.
As at 25 April 2007, the Concert so far as the Director is aware, there is no relevant Party held, in aggregate, interests in 60,550,416 Ordinary Shares audit information of which the Companys auditors in the capital of Hikma representing 35.800% of the then issued are unaware: and share capital of the Company.
On full exercise of the options under the Hikma Pharmaceuticals 2004 Stock Option Plan thethe Director has taken all the steps that he ought to have 2004 Plan and full vesting of the LTIPs, the Concert Party taken as a Director to make himself aware of any relevant would potentially have, in aggregate, interests in 62,659,557 audit information as defined and to establish that the shares in the capital of the Company representing 36.590% of Companys auditors are aware of that information.
the enlarged issued share capital of the Company, on the basis This confirmation is given and should be interpreted in that no Ordinary Shares were issued other than pursuant to the accordance with the provisions of section 234ZA of the exercise of such options or vesting of LTIPs.
During the period from the Annual General Meeting in 2007 to Deloitte & Touche LLP have expressed their willingness to 17 March 2008, the LTIP Holders together with other members continue in office as auditors and a resolution to re-appoint them of the Concert Party who hold options over Ordinary Shares will be proposed at the forthcoming Annual General Meeting.
pursuant to the 2004 Plan the Option Holders have exercised, in aggregate, options over 500,000 Ordinary Shares in the capital Annual General Meeting of the Company, of which 180,000 Ordinary Shares were sold The Annual General Meeting of the Company will be held at immediately upon exercise and 320,000 Ordinary Shares were The Andaz Hotel, 40 Liverpool Street, London EC2M 7QN on retained but subsequently disposed of by the Options Holders.
Thursday, 15 May 2008, starting at 11.00 a. m. The Notice Thus, at the date of this document including shares subscribed convening the meeting is given in a separate document by the Option Holders as part of the fund raising by the Company accompanying this document, and includes a commentary on undertaken in January 2008, the Concert Party holds interests in the business of the AGM, and notes to help shareholders exercise 66,106,123 Ordinary Shares representing 35.156% of the issued their rights at the meeting.
share capital of the Company as at the date of this document.
Approved by the Board of Directors on 17 March 2008 and Pre-emptive issue of Ordinary Shares signed on its behalf During the year under review, and in the period since 1 November 2005, the date of the Companys IPO, the Company Henry Knowles did not issue any Ordinary Shares pursuant to an authority given Company Secretary by shareholders at annual general meeting to issue Ordinary Shares for cash on a non pre-emptive basis.
Articles of Association A summary of the relevant provisions of the Companys Articles of Association the Articles is set out in the Shareholder information section on pages 101 to 103.
References to the Articles are to the existing set of Articles.
It should be noted however that the Company will adopt new Articles of Association with effect from the conclusion of the Annual General Meeting to be held on 15 May 2008.
Hikma Pharmaceuticals PLC Annual report 2007 43
